Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02546661 | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer(BISCAY) | active not recruiting | Phase 1 | 117 | AstraZenecaINDUSTRY | 5 | Dec 29, 2025 | clinicaltrials |
| NCT04592913 | Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer | active not recruiting | Phase 3 | 957 | AstraZenecaINDUSTRY | 20 | Dec 24, 2025 |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.(SOLO-1) | active not recruiting | Phase 3 | 450 | AstraZenecaINDUSTRY | 15 | Dec 10, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT05103605 | Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations(POSITHES) | active not recruiting | — | 274 | AstraZenecaINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05645172 | Retention Rate of Acalabrutinib in a Non-interventional Setting(RETAIN) | active not recruiting | — | 137 | AstraZenecaINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03703297 | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy(ADRIATIC) | active not recruiting | Phase 3 | 730 | AstraZenecaINDUSTRY | 19 | Nov 21, 2025 | clinicaltrials |
| NCT06544629 | Imjudo & Imfinzi PMS | recruiting | — | 246 | AstraZenecaINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02197234 | Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC | completed | Phase 1 | 52 | AstraZenecaINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT04068168 | Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)(Imfinzi PMS) | completed | — | 712 | AstraZenecaINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03816683 | A Disease Registry of Patients With Mantle Cell Lymphoma(SUMMIT) | completed | — | 227 | AstraZenecaINDUSTRY | 1 | Nov 14, 2025 | clinicaltrials |
| NCT03334617 | Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy(HUDSON) | active not recruiting | Phase 2 | 528 | AstraZenecaINDUSTRY | 8 | Oct 27, 2025 | clinicaltrials |
| NCT03918304 | Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS(KOREA-PLUS) | completed | — | 923 | AstraZenecaINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05215951 | Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC(MINOVA) | terminated | Phase 2 | 4 | AstraZenecaINDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT05216835 | Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 | 45 | AstraZenecaINDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT06230328 | Brazilian Reality of Hepatocellular Carcinoma(BRA-HEP) | completed | — | 300 | AstraZenecaINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05091437 | DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis(DOuBLED) | completed | — | 562 | AstraZenecaINDUSTRY | 8 | Sep 24, 2025 | clinicaltrials |
| NCT06812780 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389(CAMPOLINA) | completed | Phase 1 | 35 | AstraZenecaINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT04532645 | Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK(OVAL-1) | completed | — | 342 | AstraZenecaINDUSTRY | 3 | Sep 23, 2025 | clinicaltrials |
| NCT06131424 | NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients(iRetroBC) | completed | — | 1,151 | AstraZenecaINDUSTRY | 13 | Sep 18, 2025 | clinicaltrials |
| NCT06188494 | UNFOLD Study Egypt | completed | — | 405 | AstraZenecaINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05219162 | Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).(GPS) | completed | Phase 4 | 182 | AstraZenecaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04872621 | Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation | completed | — | 104 | AstraZenecaINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04564027 | A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 3 | Aug 29, 2025 | clinicaltrials |
| NCT01078662 | Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | completed | Phase 2 | 298 | AstraZenecaINDUSTRY | 6 | Aug 13, 2025 | clinicaltrials |
| NCT05685472 | MEDI5752 in Japanese Patients With Advanced Solid Tumors. | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT04541433 | A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer | completed | Phase 1 | 10 | AstraZenecaINDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05061134 | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition(MONETTE) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 11 | Jul 31, 2025 | clinicaltrials |
| NCT05892926 | HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia | completed | — | 204 | AstraZenecaINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04125290 | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(PROXY) | terminated | — | 2 | AstraZenecaINDUSTRY | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03534453 | Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy(L-MOCA) | completed | Phase 3 | 229 | AstraZenecaINDUSTRY | 2 | Jul 10, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT06194461 | LTFU for All Cell and Gene Therapy Studies(LOCUS) | not yet recruiting | — | 64 | AstraZenecaINDUSTRY | 4 | Jun 27, 2025 | clinicaltrials |
| NCT04613492 | A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors | terminated | Phase 1 | 40 | AstraZenecaINDUSTRY | 2 | Jun 24, 2025 | clinicaltrials |
| NCT06826677 | REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER(ARAL) | completed | — | 71 | AstraZenecaINDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04865419 | Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies | terminated | Phase 1 | 46 | AstraZenecaINDUSTRY | 6 | Jun 15, 2025 | clinicaltrials |
| NCT06324734 | Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting | completed | — | 2,506 | AstraZenecaINDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT03800134 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer(AEGEAN) | active not recruiting | Phase 3 | 825 | AstraZenecaINDUSTRY | 28 | Jun 11, 2025 | clinicaltrials |
| NCT03517917 | Prospective Tissue Collection Research Protocol | completed | — | 221 | AstraZenecaINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT04774380 | Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer(LUMINANCE) | completed | Phase 3 | 152 | AstraZenecaINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT05958134 | Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL | completed | — | 600 | AstraZenecaINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT04938141 | MEOI and HRQoL in CLL Patients Treated With BTKis | completed | — | 23 | AstraZenecaINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06231693 | Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil | terminated | — | 2 | AstraZenecaINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04991805 | Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study | completed | — | 14,000 | AstraZenecaINDUSTRY | 2 | Apr 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials